A 2016 study by Schell et al7 demonstrated that overall CRC survival varies substantially based on the number of truncating mutations in APC. For example, tumors with 1 mutation in APC, 1 mutation in APC partnering with a KRAS mutant, or 1 mutation in APC partnering with a TP53 mutant (hazard ratio [HR], 1.00) have better outcomes than tumors with 2 mutations in APC, 2 mutations in APC and a KRAS mutant, or 2 mutations in APC and a TP53 mutant (HR, 1.11). Here, TP53 is linked to colorectal carcinoma.